Research Publications

These publications result from the work of our investigators.

Soluble γ-Secretase Modulators Selectively Inhibit the Production of the 42-Amino Acid Amyloid β Peptide Variant and Augment the Production of Multiple Carboxy-Truncated Amyloid β Species.
Wagner SL, Zhang C, Cheng S, Nguyen P, Zhang X, Rynearson KD, Wang R, Li Y, Sisodia SS, Mobley WC, Tanzi RE.
Biochemistry
Publish date: 2014 Jan 22. [Epub ahead of print]
PMID: 24401146

Human chromosome 21 orthologous region on mouse chromosome 17 is a major.
Zhang L, Meng K,  Liu C, Pao A, Belichenko PV, Kleschevnikov AM, Josselyn S, Liang P, Ye P, Mobley WC, Yu YE. 
Publish date: 2013 Sep 25. [Epub ahead of print]
PMID: 24041763

Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC.
Publish date: 2012
PMID: 22764230

Genetic analysis of Down syndrome facilitated by mouse chromosome engineering.
Zhang L, Fu D, Belichenko PV, Liu C, Kleschevnikov AM, Pao A, Liang P, Clapcote SJ, Mobley WC, Yu YE
Publish date: 2012, Jan 1
PMID: 22126738

Discoveries in Down syndrome: Moving basic science to clinical care.
Kleschevnikov A.M., Belichenko P.V., Salehi A., Wu C.
Publish date: 2012
PMID: 22541294

Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.
Kleschevnikov AM,Belichenko PV,Gall J,George L,Nosheny R,Maloney MT,Salehi A,Mobley WC.
Publish Date: 2012 Feb
PMID :22062771

Genetic analysis of Down syndrome facilitated by mouse chromosome engineering.
Zhang L,Fu D,Belichenko PV,Liu C,Kleschevnikov AM,Pao A,Liang P,Clapcote SJ,Mobley WC,Yu YE.
Publish Date: 2012 Jan 1
PMID :22126738

Mouse models for down syndrome-associated developmental cognitive disabilities.
Liu C,Belichenko PV,Zhang L,Fu D,Kleschevnikov AM,Baldini A,Antonarakis SE,Mobley WC,Yu YE.
Publish Date: 2011
PMID :21865664

Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
Faizi M,Bader PL,Tun C,Encarnacion A,Kleschevnikov A,Belichenko P,Saw N,Priestley M,Tsien RW,Mobley WC,Shamloo M.
Publish Date :2011 Aug
PMID :21527343

Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease.
Rissman RA,Mobley WC.
Publish Date :2011 May
PMID :21388375

Mouse models for down syndrome-associated developmental cognitive disabilities.
Liu C,Belichenko PV,Zhang L,Fu D,Kleschevnikov AM,Baldini A,Antonarakis SE,Mobley WC,Yu YE.
Publish Date :2011
PMID :21865664

Belichenko P.V., Kleschevnikov A.M. (2011) Deficiency of adult neurogenesis in the Ts65Dn mouse model of Down syndrome. In: Genetics and Etiology of Down syndrome, edited S. Dey. InTech Publisher, pp. 177-192. www.intechopen.com ISBN 978-953-307-631-7

Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of down syndrome.
Popov VI, Kleschevnikov AM, Klimenko OA, Stewart MG, Belichenko PV.
Publish Date: May 1, 2011
PMID: 21452200

Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice.
Yu T,Liu C,Belichenko P,Clapcote SJ,Li S,Pao A,Kleschevnikov A,Bechard AR,Asrar S,Chen R,Fan N,Zhou Z,Jia Z,Chen C,Roder JC,Liu B,Baldini A,Mobley WC,Yu YE.
Publish Date: Dec. 17, 2010
PMID: 20932954

Deficiencies in the region syntenic to human 21q22.3 cause cognitive deficits in mice.
Yu T,Clapcote SJ,Li Z,Liu C,Pao A,Bechard AR,Carattini-Rivera S,Matsui S,Roder JC,Baldini A,Mobley WC,Bradley A,Yu YE.
Publish Date: June 2010
PMID: 20512340

Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome.

Salehi A,Faizi M,Colas D,Valletta J,Laguna J,Takimoto-Kimura R,Kleschevnikov A,Wagner SL,Aisen P,Shamloo M,Mobley WC.
Publish Date: Nov. 18, 2009
PMID: 20368182

The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome.
Mégarbané A, Ravel A, Mircher C, Sturtz F, Grattau Y, Rethoré MO, Delabar JM, Mobley WC.
Publish Date: September 2009
PMID :19636252

The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.
Belichenko NP,Belichenko PV,Kleschevnikov AM,Salehi A,Reeves RH,Mobley WC.
Publish Date: May 6, 2009
PMID: 19420260

Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome.

Belichenko PV,Kleschevnikov AM,Masliah E,Wu C,Takimoto-Kimura R,Salehi A,Mobley WC.
Publish Date: Feb. 1, 2009
PMID: 19034952

The coming of age of axonal neurotrophin signaling endosomes.
Wu C,Cui B,He L,Chen L,Mobley WC.
Publish Date: Feb. 15, 2009
PMID: 19028611

Sleep and EEG features in genetic models of Down syndrome.
Colas D,Valletta JS,Takimoto-Kimura R,Nishino S,Fujiki N,Mobley WC,Mignot E.
Publish Date: April 2008
PMID: 18282758

Using mouse models to explore genotype-phenotype relationship in Down syndrome.
Salehi A,Faizi M,Belichenko PV,Mobley WC.
Publish Date: 2007
PMID: 17910089

Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.
Belichenko PV,Kleschevnikov AM,Salehi A,Epstein CJ,Mobley WC.
Publish Date: Oct. 1, 2007
PMID: 17663443

Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.
Salehi A,Delcroix JD,Belichenko PV,Zhan K,Wu C,Valletta JS,Takimoto-Kimura R,Kleschevnikov AM,Sambamurti K,Chung PP,Xia W,Villar A,Campbell WA,Kulnane LS,Nixon RA,Lamb BT,Epstein CJ,Stokin GB,Goldstein LS,Mobley WC.
Publish Date: July 6, 2006
PMID: 16815330

Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12.
Villar AJ,Belichenko PV,Gillespie AM,Kozy HM,Mobley WC,Epstein CJ.
Publish Date: February 2005
PMID: 15859352

Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome.
Belichenko PV,Masliah E,Kleschevnikov AM,Villar AJ,Epstein CJ,Salehi A,Mobley WC.
Publish Date: Dec. 13, 2004
PMID: 15515178

Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.
Kleschevnikov AM,Belichenko PV,Villar AJ,Epstein CJ,Malenka RC,Mobley WC.
Publish Date: Sept. 15, 2004
PMID:15371516

Trafficking the NGF signal: implications for normal and degenerating neurons.
Delcroix JD,Valletta J,Wu C,Howe CL,Lai CF,Cooper JD,Belichenko PV,Salehi A,Mobley WC.
Publish Date: 2004
PMID: 14699953

Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion.
Cooper JD,Salehi A,Delcroix JD,Howe CL,Belichenko PV,Chua-Couzens J,Kilbridge JF,Carlson EJ,Epstein CJ,Mobley WC.
Publish Date: Aug. 28, 2001
PMID: 11504920